公开(公告)号：US20250002916A1

公开(公告)日：2025-01-02

申请号：US18708953

申请日：2022-11-09

Applicant: EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION ,  VASTHERA CO. LTD.

Inventor： Sang Won KANG ,  Sang-Hyuk LEE ,  Yerin KIM

IPC: C12N15/113 ,  C12Q1/6851 ,  C12Q1/6883

Abstract: The present invention relates to a pharmaceutical composition comprising a microRNA (miRNA) inhibitor as an active ingredient for the prevention or treatment of a vascular smooth muscle cell proliferative disease; a kit comprising a miRNA-detectable agent for the diagnosis of a vascular smooth muscle cell proliferative disease; a method for providing information for the diagnosis of the diseases; and a therapeutic method. Discovered in the present invention were the miRNA subsets miR-132-3p, miR-370-3p, miR-130b-5p, and miR-410-3p that are involved in proliferative diseases of smooth muscle cells. It was found that these miRNAs significantly increased their expression 5-fold or more in damaged arteries, compared to the control, and in particular, miR-370-3p was highly expressed in coronary tissues of atherosclerosis patients. Thus, the miRNAs can be advantageously used for diagnosing diseases related thereto and further can find applications in treating vascular smooth muscle cell proliferative diseases.

公开(公告)号：US20220323453A1

公开(公告)日：2022-10-13

申请号：US17639295

申请日：2020-08-25

Applicant: VASTHERA CO. LTD.

Inventor： Sang Won KANG

IPC: A61K31/549 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of solid cancer comprising an epidithiodioxopiperazine derivative compound based on a parent structure comprising an intramolecular disulfide bridge in an epidithiodioxopiperazine ring or a pharmaceutically acceptable salt thereof as an active ingredient.